Pulmonary Arterial Pressure Above 30 mmHg Linked to Increased...
WEBby Iqra Mumal, MSc July 8, 2019. An estimated right ventricular systolic pressure (eRVSP) — a measure of the pressure inside the artery that supplies blood to the lungs (pulmonary artery) — greater than 30.0 mmHg is related to an increased risk of mortality in patients with pulmonary hypertension (PH), according to a new Australian study.
For PAH Treatment, Mylan Launches Tadalafil Tablets, 1st Generic...
WEBAug 22, 2018 · Mylan Announces U.S. Launch of 20 mg Tadalafil Tablets, 1st Generic of Adcirca for PAH Treatment. by Iqra Mumal, MSc August 22, 2018. Mylan recently introduced a formulation of 20 mg tadalafil tablets, the first generic version of Eli Lilly ‘s Adcirca, in the United States for patients with pulmonary arterial hypertension (PAH).
Gilead’s Letairis with Tadalafil Approved by FDA for Pulmonary...
WEBOct 5, 2015 · Gilead Sciences announced that the U.S. Food and Drug Administration (FDA) has approved Letairis ® (ambrisentan) with tadalafil for pulmonary arterial hypertension (PAH) to diminish disease progression risk and hospitalization and to improve the ability to exercise — a decision that directly follows recent study results indicating the efficacy of the combination therapy in PAH patients.
New PAH Drug from Actelion Approved by FDA – Pulmonary...
WEBJan 5, 2016 · by Margarida Azevedo, MSc January 5, 2016. According to a recent announcement, the United States Food and Drug Administration (FDA) approved Actelion Pharmaceuticals’ Uptravi (selexipag) tablets for the treatment of adult patients with pulmonary arterial hypertension (PAH) to delay disease progression and reduce the risk of hospitalization ...
Aria Raises $31M for Planned Study of Balloon Implant to Treat PAH
WEBMar 2, 2020 · Aria CV announced the end of a funding round that will be used to finance a feasibility study of its medical device, the Pulmonary Hypertension System (Aria CV PH System), in people with pulmonary arterial hypertension (PAH) in the U.S. The series B round, which raised $31 million, was led by Xeraya Capital. “Aria …
Gilead Announces Encouraging Results For Combined...
WEBAug 31, 2015 · Gilead Sciences, Inc. recently announced the publication of data in The New England Journal of Medicine concerning the AMBITION trial evaluating the combination therapy of Letairis® (ambrisentan) and tadalafil for pulmonary arterial hypertension (PAH). The AMBITION trial (NCT01178073) is a multicenter, randomized, double-blind Phase 3 study developed in collaboration with GlaxoSmithKline (GSK).
FDA Names SoniVie’s TIVUS System a Breakthrough Device for PAH
WEBSep 11, 2019 · FDA Grants Breakthrough Device Status to SoniVie’s TIVUS System for PAH. by Joana Carvalho, PhD September 11, 2019. The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough device to SoniVie’s Therapeutic Intra-Vascular Ultrasound (TIVUS) System for the treatment of people with pulmonary arterial hypertension ...
Tyvaso Becomes 1st PH-ILD Treatment Approved in US
WEBApr 1, 2021 · The U.S. Food and Drug Administration (FDA) approved Tyvaso, developed by United Therapeutics, to improve exercise ability in PH-ILD patients, the company said. “The regulatory approval of Tyvaso, an inhaled treatment, is exciting news both for patients with PH-ILD and the physicians who treat adults living with this serious, life-threatening disease” — for which there were no approved ...
Third Pole's portable inhaled nitric oxide device clears early study
WEBMar 1, 2024 · Third Pole Therapeutics said it has successfully completed an early feasibility study of its portable inhaled nitric oxide (iNO) delivery device, eNOfit, allowing the company to move to larger trials for pulmonary hypertension (PH) associated with interstitial lung disease. eNOfit is designed to provide patients with mobile treatment at home or ...
Complexa Starts Dosing in Phase 2 Trial to Evaluate CXA-10 for PAH
WEBFeb 22, 2019 · The PRIMEx study (NCT03449524) was planned to evaluate the safety, efficacy, and overall stability and distribution in the body of two doses of CXA-10 in adults with PAH while on stable background therapy.The trial is expected to enroll up to 115 participants across 45 study centers in the United States and Europe. For more information about locations and contacts, visit the trial site.